{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:19:57Z","timestamp":1787566797920,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001200"],"award-info":[{"award-number":["MOH-001200"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-000153"],"award-info":[{"award-number":["MOH-000153"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eclinm.2026.104059","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:53:39Z","timestamp":1784397219000},"page":"104059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Frailty status, clinical and functional outcomes in cardiac amyloidosis: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4801-7306","authenticated-orcid":false,"given":"Haowen","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Yuan","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.M.","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-4543","authenticated-orcid":false,"given":"Raymond","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-San","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-9732","authenticated-orcid":false,"given":"Angela S.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104059_bib1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2026.104059_bib2","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2024078","article-title":"Temporal trends in the prevalence, incidence, and mortality of cardiac amyloidosis in Korea over 12 years","volume":"46","author":"Choi","year":"2024","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.eclinm.2026.104059_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis\u2013associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.eclinm.2026.104059_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00392-022-02114-y","article-title":"Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018","volume":"112","author":"Ney","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.eclinm.2026.104059_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaccao.2021.05.004","article-title":"Two decades of cardiac amyloidosis: a Danish nationwide study","volume":"3","author":"Westin","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.eclinm.2026.104059_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-14526-7","article-title":"Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study","volume":"15","author":"Vaena","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.104059_bib7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.eclinm.2026.104059_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.eclinm.2026.104059_bib9","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2026.104059_bib10","first-page":"102","article-title":"A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction","volume":"12","author":"Magdi","year":"2022","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.eclinm.2026.104059_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2026.104059_bib12","series-title":"StatPearls","article-title":"Transthyretin amyloid cardiomyopathy (ATTR-CM)","author":"Jain","year":"2025"},{"key":"10.1016\/j.eclinm.2026.104059_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/HCO.0000000000001198","article-title":"New therapies to treat cardiac amyloidosis","volume":"40","author":"Nguyen","year":"2025","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104059_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/eurheartj\/ehaf667","article-title":"Transthyretin amyloid cardiomyopathy: from cause to novel treatments","volume":"47","author":"Fontana","year":"2026","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104059_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ehjqcco\/qcaf109","article-title":"Clinical outcomes following invasive cardiovascular interventions in frail populations: a systematic review and meta-analysis","volume":"12","author":"Jiang","year":"2026","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.eclinm.2026.104059_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101889","article-title":"Effect of frailty on cardiovascular clinical trials: a systematic review and meta-analysis","volume":"4","author":"Jiang","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.eclinm.2026.104059_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11886-025-02308-6","article-title":"The weight of comorbidities in the specific treatment of ATTR-related amyloid cardiomyopathy","volume":"27","author":"Cantone","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.eclinm.2026.104059_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jaccao.2025.01.018","article-title":"Clinical phenotype and prognostic significance of frailty in transthyretin cardiac amyloidosis","volume":"7","author":"Fumagalli","year":"2025","journal-title":"JACC CardioOncology"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104059_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.125.012777","article-title":"Prognostic value of malnutrition, frailty, and physical performance in transthyretin cardiac amyloidosis: insights from a prospective multicenter cohort study","volume":"18","author":"Fumagalli","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.eclinm.2026.104059_bib20","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.3390\/jcm10153415","article-title":"Frailty in wild-type transthyretin cardiac amyloidosis: the tip of the iceberg","volume":"10","author":"Broussier","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.eclinm.2026.104059_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101784","article-title":"Cardiac amyloidosis in older adults with a focus on frailty: JACC: advances expert consensus","volume":"4","author":"Bart","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.eclinm.2026.104059_bib22","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.104059_bib23","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2026.104059_bib24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.eclinm.2026.104059_bib25","author":"Wells"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104059_bib26","article-title":"Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis","volume":"10","author":"Nayebirad","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.eclinm.2026.104059_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jclinepi.2014.09.005","article-title":"Cochran's Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy","volume":"68","author":"Cohen","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2026.104059_bib28","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"on behalf of the Cochrane Statistcal Methods Group. Analysing data and undertaking meta-analyses","author":"Deeks","year":"2019"},{"key":"10.1016\/j.eclinm.2026.104059_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40520-024-02750-6","article-title":"Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study","volume":"36","author":"Fumagalli","year":"2024","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.eclinm.2026.104059_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ehf2.15026","article-title":"Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis","volume":"12","author":"Broussier","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.eclinm.2026.104059_bib31","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.3390\/jcm12247507","article-title":"Frailty in older patients with transthyretin cardiac amyloidosis","volume":"12","author":"Cazalbou","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.eclinm.2026.104059_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/13506129.2024.2319133","article-title":"Gait abnormalities in older adults with transthyretin cardiac amyloidosis","volume":"31","author":"Petros","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.eclinm.2026.104059_bib33","article-title":"The 6-min walk test in transthyretin cardiac amyloidosis: prognostic utility put to the real-world test","volume":"12","author":"Poledniczek","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.eclinm.2026.104059_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-Minute walk test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2026.104059_bib35","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00392-026-02848-z","article-title":"Current treatment decisions in cardiac transthyretin amyloidosis: a multicentre analysis","volume":"115","author":"Lavall","year":"2026","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.eclinm.2026.104059_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008105","article-title":"Prevalence and prognostic significance of frailty among patients with transthyretin amyloidosis cardiomyopathy","volume":"14","author":"Fine","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.eclinm.2026.104059_bib37","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.3390\/jcm13185490","article-title":"Baseline predictors of adverse outcomes for transthyretin amyloidosis cardiomyopathy patients treated and untreated with tafamidis: a Canadian referral center experience","volume":"13","author":"Shahi","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.eclinm.2026.104059_bib38","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ejhf.3622","article-title":"Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis","volume":"27","author":"Longinow","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.eclinm.2026.104059_bib39","article-title":"Prognostic value of the 6-minute walk test and clinical characteristics of patients with transthyretin amyloid cardiomyopathy","volume":"37","author":"Romero","year":"2024","journal-title":"Int J Cardiovasc Sci"},{"key":"10.1016\/j.eclinm.2026.104059_bib40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/ggi.14268","article-title":"Progressive deterioration of frailty is associated with poor outcomes in patients with transthyretin cardiac amyloidosis","volume":"21","author":"Takahashi","year":"2021","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.eclinm.2026.104059_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036755","article-title":"Predictors of early death in patients with wild-type transthyretin cardiac amyloidosis","volume":"14","author":"Milani","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.eclinm.2026.104059_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102903","article-title":"Prevalence of frailty in cardiac transthyretin amyloidosis: a systematic review and meta-analysis","volume":"113","author":"Finazzi","year":"2026","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.eclinm.2026.104059_bib43","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","article-title":"Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial","volume":"146","author":"Butt","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2026.104059_bib44","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/M21-4776","article-title":"Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial","volume":"175","author":"Butt","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2026.104059_bib45","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2022.06.037","article-title":"Sacubitril\/valsartan and frailty in patients with heart failure and preserved ejection fraction","volume":"80","author":"Butt","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2026.104059_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14029","article-title":"Effect of canakinumab on frailty: a post hoc analysis of the CANTOS trial","volume":"23","author":"Orkaby","year":"2024","journal-title":"Aging Cell"},{"key":"10.1016\/j.eclinm.2026.104059_bib47","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029588","article-title":"Association between claims-defined frailty and outcomes following 30 versus 12 months of dual antiplatelet therapy after percutaneous coronary intervention: findings from the EXTEND-DAPT study","volume":"12","author":"Faridi","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.eclinm.2026.104059_bib48","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.121.011375","article-title":"Impact of frailty and prefrailty on outcomes of transcatheter or surgical aortic valve replacement","volume":"15","author":"Arnold","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.eclinm.2026.104059_bib49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104059_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104059_bib51","first-page":"364","article-title":"Serial changes in cardiopulmonary exercise testing parameters in untreated patients with transthyretin cardiac amyloidosis","volume":"40","author":"Argir\u00f2","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.eclinm.2026.104059_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlc.2024.06.023","article-title":"Frailty prevalence and characteristics in a transthyretin amyloid cardiomyopathy cohort","volume":"33","author":"Montgomery","year":"2024","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.eclinm.2026.104059_bib53","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/eurheartj\/ehae923","article-title":"Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study","volume":"46","author":"Debonnaire","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2026.104059_bib55","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:28:27Z","timestamp":1787560107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":54,"alternative-id":["S2589537026003123"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104059","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frailty status, clinical and functional outcomes in cardiac amyloidosis: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104059"}}